Heart failure & cardiomyopathies
Rationale for and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial
Study context
- Population
- Patients with best-available imaging confirmed left ventricular (LV) thrombusplanned
- Participants
- 216 patients
- Planned comparison
- DOAC vs warfarin
- Primary endpoint
- Resolution of LV thrombus without CV death, stroke, systemic embolism or major bleeding
- Follow-up
- 3-month follow-up
Methodological detailsdesign paper, noninferiority, prospective, 1:1 randomisation, 16 centres in New Zealand and Australia, Follow-up 3 years for long-term management and outcomes, Recruitment underway, Secondary endpoints: components of primary outcome, change in thrombus diameter, days alive and out of hospital, disability free survival, quality of life
- Design paper
- Noninferiority
- Prospective
- 1:1 randomisation
- 16 centres in New Zealand and Australia
- Follow-up 3 years for long-term management and outcomes
- Recruitment underway
- Secondary endpoints: components of primary outcome, change in thrombus diameter, days alive and out of hospital, disability free survival, quality of life
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale for and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial. Am Heart J. Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →